What the business is, and whether it's a good one at a fair price.
Operates a chain of multi-specialty hospitals across western and central India — Thane, Pune, Indore and the newly commissioned Dombivli — earning ₹1,499.8 crore in FY26 (+15.2% YoY). The Dombivli greenfield (500-bed capacity with 300 beds currently fitted out across 750,000 sq ft) opened in February 2026 two months ahead of schedule, and a 400-bed quaternary-care hospital is being set up on a one-lakh-sq-ft site in BKC Mumbai, with further projects in the pipeline at Pune South, Mira Road and Thane, taking the long-term bed-count target to roughly 3,000. Revenue is driven by inpatient and outpatient volumes — 10.8 lakh volumes in FY26, with Average Revenue Per Occupied Bed at ₹67,700 and Average Length of Stay of 3.87 days; insurance payers contributed 55.4% of FY26 revenue and government schemes 1%. The model is asset-heavy and expansion-driven: FY26 capex was deployed across Dombivli, BKC land, Pune and Mira Road, with gross debt at ~₹500 crore against cash of ~₹545 crore, leaving the balance sheet net cash positive. Other operating expenses (40.9% of revenue) and employee costs (17.1%) are the largest cost lines, followed by depreciation at 5.8%. A subsidiary has separately acquired Sulcus Private Limited to set up an IV fluids and pharmaceutical manufacturing facility near Ujjain with ₹35–40 crore of further investment planned.
Measured from the filed financials, judged against its Hospital peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from JUPITER LIFE LINE HOSP L's filed financials and exchange disclosures
JUPITER LIFE LINE HOSP L is a Healthcare Services company listed on NSE and BSE, trading under the symbol JLHL.
Yes. Over the trailing twelve months JUPITER LIFE LINE HOSP L reported a net profit of ₹186 Cr on revenue of ₹1,558 Cr.
Yes. The dividend yield is 0.36% at the current price. It paid out 3% of its profit as dividend in FY26.
No. Debt stands at 0.33× equity, and it carries net debt of ₹454 Cr. That is lower than 26% of its 24 Hospital peers.
On trailing P/E, JUPITER LIFE LINE HOSP L ranks 3 of 30 in Hospital — cheaper than 93% of them, against an industry median of 47.3×. This is a position, not a valuation judgement.
Every NSE and BSE filing by JUPITER LIFE LINE HOSP L appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.